morbidity during the first 5 years of life (1, 2 ) . The information provides healthcare workers with an opportunity to arrange prompt medical supervision, including prophylactic penicillin, counseling, and education for affected families.
Universal neonatal hemoglobinopathy screening programs in the United Kingdom are recommended where the minority ethnic population exceeds 15% (3 ) . Central Middlesex Hospital (CMH) 3 in northwest London tests all babies born in the North Thames (West) health region, ϳ50 000 births per year. Maternal consent is sought before the taking of samples. The population of region is 19% non-Caucasian, with individual districts ranging from 3% to 61%. For the past 9 years, this laboratory has used isoelectric focusing (IEF; Isolab) to screen neonates for hemoglobin disorders. Although the results have been found to be satisfactory, this is a labor-intensive manual technique, and the need has arisen to identify a suitable automated method capable of replacing the existing system. For this purpose, we chose the Bio-Rad Variant HPLC system (Bio-Rad Laboratories).
There are several programs available for this system. One program is the Sickle Cell Short Program, which is a rapid 3-min assay and uses either filter paper blood spots or whole blood samples. This program is specifically designed to provide a qualitative result for hemoglobins (Hbs) A, F, S, C, D, and E in the neonate.
Another program is the ␤-Thalassemia Short Program, which is a 6.5-min assay designed to quantify Hbs A 2 and F. The performance of this program for the quantification of these Hbs and the identification of other Hbs, including A, S, C, D, and E, in adult samples has been described elsewhere (4 -6 ) .
For the purposes of neonatal screening as described here, a qualitative result is all that is required initially.
Because of this, and the desire for a more rapid assay, the Sickle Cell Short Program was chosen as the test method.
In this evaluation, we compared "back-to-back" the efficiency and suitability of HPLC for neonatal hemoglobinopathy screening against the established technique of IEF. This included a direct comparison of results, an estimation of the lower limit of detection of both methods, and observation of carryover and the effects of dried blood spot degradation in the HPLC method.
Materials and Methods
This study was undertaken during a 15-month period in the CMH neonatal screening laboratory. Results from both systems were determined in the same laboratory, but the work was arranged so that the interpreter of the HPLC chromatograms was unaware of the IEF results a priori. During the study period, 25 750 samples of the screening program's total of 51 230 samples were tested using HPLC.
samples
Heel prick samples taken 7 days after birth onto Schleicher & Schuell grade 903 filter paper were used. The 3-mm spots used for both assays yielded a mean Hb concentration of 18.0 g/L (range, 7.9 -20.5 g/L). Spots were tested with both methods on the day of receipt or at the latest on the next working day. Before and after testing, specimens were stored between 2 and 8°C.
cation-exchange hplc
The Bio-Rad Variant Hemoglobin Testing System is an automated HPLC instrument that uses a minicartridge filled with a cation-exchange polymer material. Following the manufacturer's guidelines, we punched 3-mm blood spots from the filter paper and eluted them with 0.5 mL of distilled water for 20 min. The system uses two phosphate elution buffers, of differing concentrations, that are introduced into the flow-stream at a controlled rate of 2 mL/min. Each sample was injected into the flow stream via an automatic probe. As the concentration of the mixture increased, the more strongly retained hemoglobins eluted from the cartridge. Changes in absorbance were measured using a dual-wavelength filter photometer, and these changes were plotted against time. Each Hb has a characteristic retention time. Chromatograms showing the results graphically and as numerical data were printed automatically for each sample within 3 min of the injection. The maximum batch size was 100 samples, with a run time of 5 h and a preparation time of ϳ20 min. The manufacturer provides Hb FAES and Hb FADC controls, artificial mixtures of hemoglobin containing the approximate concentrations expected in neonatal samples, and these were tested at the beginning and end of each analytical run.
The researcher examined each chromatogram and recorded the results on a worksheet, later transcribing the IEF results onto the same sheet. In all cases of discrepancy between the two techniques, the sample cards were repunched and retested using both methods.
ief
The IEF analysis used a precast agarose gel placed on a horizontal water-cooled tank unit. Blood spots (3 mm) were punched from the filter paper sample and eluted with 50 L of elution solution for a minimum of 30 min. A template was used to apply the eluate, and 50 W was applied until discrete bands were visible (usually ϳ2 h). The plate was then fixed with 100 g/L trichloroacetic acid, rinsed with water, and stained with 2 g/L o-dianisidine in methanol (7 ) . A total of 72 samples and 4 FASC controls were tested on each plate. Identification in the first instance was visual, using control positions as guides, with each plate being independently read by three different readers, of which two were experienced senior staff.
All samples with abnormalities were repunched and repeated on subsequent IEF plates, using appropriate controls. Samples that appeared inadequately focused or that had merged with adjacent samples on the gel were repeated. Babies without Hb A or with a variant other than Hb S or Hb C were recalled for retest at 6 weeks of age.
establishing the limitations of the method Each chromatogram that followed a positive result was examined for carryover from the previous sample. Carbon tetrachloride hemolysates prepared from known Hb SS and CC patients whose blood contained Ͻ2% Hb F (quantification determined with Shimadzu IE-HPLC; Dyson Instruments) were added to a known Hb FA cord blood sample to achieve percentages of Hb S or C serially from 0.2% to 2%. To ascertain the lower limits of detection, subsamples at each stage of dilution were tested with both IEF and HPLC.
Results

common traits and diseases
The percentages of confirmed abnormal Hb types found during the test period are shown in Fig. 1 . The most common phenotype observed in this study was sickle cell trait (60%). The Hb C trait, prevalent in peoples of West African ancestry, was the next most common abnormality detected (16%). Thirty-nine infants (4%) were confirmed to have hemoglobin disorders of clinical relevance.
The HPLC and IEF results are summarized in Table 1 . HPLC detected all of the diseases detected by IEF except for one double heterozygote, in which the printed chromatogram was entirely normal (Table 2) . When detecting sickle cell trait (FAS) and Hb C trait (FAC) present in the neonate, HPLC was successful in 100% of cases that were detected by IEF.
There were 57 cases of FAD reported at the initial screen by IEF, 53 of which were confirmed by repeat testing at 6 weeks: 49 as AD-Punjab; 3 as AD-Iran, and 1 as AD-Korle Bu. Follow-up was not possible in four neonates. In all cases in which Hb D was detected using IEF, an abnormality was detected by HPLC. However, only cases of D-Punjab (the most prevalent Hb D type in the region) were detected in the window for Hb D in the HPLC method. Hb D-Iran was observed in, or very near, the window for Hb E in the HPLC method. Hb D-Korle Bu moved marginally slower (0.1 mm) than D-Punjab and D-Iran on IEF. In the one case of Hb D-Korle Bu detected by IEF, the Hb was in the window for Hb E.
FAE, or Hb E trait, was detected by IEF in 69 cases, 63 of which were confirmed at 6 weeks. Six cases were lost to follow-up. HPLC detected all of the cases of Hb E that IEF detected plus one additional. In this case, upon reexamination of the original IEF plate, a very faint band was observed ( Table 2 ).
In addition, in the HPLC method, there were 11 cases in which an abnormality was observed in the window for Hb D and 9 cases in which an abnormality was observed in the window for Hb E for which the abnormality was not identified as Hb D or E by IEF. These cases were reported initially as FA ϩ Band(s) by IEF, and most were subsequently confirmed and typed, and are detailed in the Discussion.
less common abnormalities
HPLC also detected various abnormalities outside its design capabilities for Hbs A, F, S, C, D, and E. In 71 cases, the chromatograms showed anomalies, mainly in the "Fast" region, the "Unknown 2" region (between Hb F and Hb A), and the area between Hb S and Hb C. In one additional case, a definite abnormality was observed in the window for Hb E in the HPLC method, but was not detected by IEF. This band was noted on repeat IEF in a position 1 mm slower than Hb F, and review of the Table 2 for details of the discrepancies. b Two were retested at 6 weeks of age and found to be normal. In the third case, the family refused the retest. c In the five discrepancies, no abnormalities were observed with HPLC. Two were probable ␥-chain variants. original plate demonstrated poor focusing, which obscured detection (Table 2 ). In three other instances, a possible abnormality-a slight peak between Hb F and Hb A-was detected by HPLC, but the IEF results were normal. Two of these infants were resampled at 6 weeks of age and found to be normal (FA) by HPLC and by all other methods, including IEF. The third family refused the retest.
Thirty-four bands detected at birth by IEF were found to be much reduced or to have disappeared at the time of the 6-week repeat testing. These were classified as ␥-chain variants and could not be investigated further. HPLC detected 24 of these ␥-chain variants, whereas 10 were not observed either at the initial testing or at the 6-week repeats.
In four cases, the presence of a heterozygous variant was detected by IEF and confirmed by the laboratory at 6 weeks, but was not detected by HPLC ( Table 2) . One of these cases was identified as Hb Chicago, and the other three are still under investigation.
Seventeen additional cases were lost to follow-up. Five of these were not detected by HPLC; two were thought to be the ␥-chain variant F-Sardinia. Table 3 gives a breakdown of the Hb types confirmed during the test period. Confirmation methods included cellulose acetate, acid gel and globin chain electrophoresis, urea triton, amino acid analysis, and mass spectrometry. With the exception of Hbs Chicago and Harrow, all were detected by HPLC. In addition to those that appeared in the windows for Hbs D and E, the other abnormalities observed fell outside the preset windows of the HPLC system. Examples of chromatograms are shown in Fig. 2 .
Hb barts Hb Barts (␥4) occurs in fetal life in ␣-thalassemia when there are reduced ␣ chains available. In the neonate, Hb Barts is recognized as two or three very fast-running bands on IEF. Studies have shown that the degree of Hb Barts present in the neonate is suggestive of the number of nonfunctional or deleted ␣ genes and thus the severity of the ␣-thalassemia (8 ) . At CMH, only when three Hb Barts bands are present on IEF, with the middle band approximately equal in appearance to the Hb A, are babies resampled at 6 weeks of age. This is done to test for Hb H disease, which is characterized by moderately severe anemia and three nonfunctional ␣ genes. Since 1989, only five cases of Hb H disease have been identified by CMH, with none observed during the test period.
HPLC was capable of detecting Hb Barts in routine analysis. Hb Barts appears as a distinct, increased peak in the Fast region (first peak observed) on the chromatogram (Fig. 2) . HPLC detected 208 cases of such an increase in the Fast region (values ranging from 4% to 23% Fast). Each case was compared with the corresponding sample tested on IEF. Fig. 3 shows all 208 such cases observed by HPLC, and the corresponding IEF result. A Student t-test performed between the "observed" and "not observed" groups demonstrated a significant difference in the means between the groups (P ϭ 0.0000; ␣ ϭ 0.05). In 58 cases detected by HPLC (varying from 3% to 9% Fast), no Hb Barts was observed on IEF. This may be because IEF is not a sensitive test for Hb Barts, and it is possible that many of the cases of increased Fast observed by HPLC, but not by IEF, are in fact true cases of single nonfunctional or deleted ␣ genes. There were six instances in which Hb Barts was observed on IEF but there was no increased peak observed on the corresponding chromatogram. Without genetic analysis, which was not within the scope of this study, no further explanation can be given with regard to these anomalies. Hb H disease was not apparent in any of these cases.
carryover and limits of detection
No carryover was observed at any time during the test period during routine neonatal analysis using HPLC. The lower limits of detection are shown in Table 4 . The IEF results were determined blind on day 0 from hemolysates poured onto filter paper cards. HPLC results were determined from fresh hemolysates diluted on day 0.
The IEF results were very similar to those reported previously for the detection of Hb S and Hb C (9 ), although we were able to produce a detection limit of Ͻ0.5% for Hb C and Ͻ0.75% for Hb S, in contrast to the previous report in which detection by HPLC was successful at 1% Hb abnormality or higher.
degradation
The effect of aging of the dried blood spots on the HPLC analysis was tested without back-to-back IEF testing because the minimal effects of storage on results from IEF have been well established (10, 11 ) . Wajcman et al. (10 ) successfully performed IEF analyses on samples that had been stored at 4°C for up to 18 months.
Between 2 and 4 months after the initial testing, 20 heel prick samples (randomly chosen from a larger sample representing many of the various abnormal Hbs) were retested using HPLC. Although high baselines, increased noise in the Fast region, and wider areas for both normal and abnormal Hbs were noted, the results were satisfactory for Hbs A, F, S, and C except from premature infants born at 35 weeks gestation or less. However, ambiguous results were observed in cases of other abnormalities (especially ␣-chain variants that occur in small percentages in the neonate) and Hb Barts. 
Discussion
This study addressed many of the issues that laboratories need to debate when deciding whether to adopt IEF or HPLC as the primary screen for neonatal hemoglobinopathy programs. The relative advantages of both techniques are discussed below. Costing data from our laboratory reported elsewhere (12 ) demonstrated only marginal differences between techniques for programs screening Ͼ25 000 births annually. The Bio-Rad Variant has interchangeable programs for quantitative analysis of Hbs A 2 and F in nonneonates and for Hb A 1c in diabetics.
The capacity of a single HPLC system using this type of rapid program is ϳ230 patient samples per 8-h working day. One hundred samples can be analyzed during a 5-h period essentially unaided, and 20 -30 samples can be analyzed before the last batch of 100, which can continue after regular work hours. The system shuts down automatically at the end of the run. However, some time must be allowed for routine maintenance and running retention markers; therefore, 200 patient samples per day is more realistic. This means that one system should be adequate for a laboratory testing of up to 50 000 samples per year. When IEF is used, 72 samples can be tested in 2 h, giving a daily workload of 432 samples for one tank. Each power pack and cooler can run two tanks; therefore, the capacity can be doubled for little extra capital cost.
IEF plates cannot be read until the plate is dry, usually overnight, whereas results from HPLC are available 3 min after sample injection. In addition, the STAT option on the Bio-Rad Variant allows urgent queries to be met. In our experience, however, such urgent results are rarely requested (less than one per year).
When performed correctly, IEF produces excellent hemoglobin separation, with very little band overlap when bands are measured to 0.1 mm against controls. However, results obtained with IEF can be inconsistent because of variable application and staining techniques. Sample merging and insufficient focusing occur even with experienced staff, leading to a substantial number of otherwise unnecessary repeats. The manufacturer's guidelines for sample preparation for the HPLC method are simple and lead to very few technical repeats.
When IEF is used, samples are first punched and eluted in microtiter plates and then transferred by pipette to the appropriate position on the gel template. Not only is there the possibility of a punching error, there is the risk of a pipetting error at the sample application stage. The biggest single advantage of automated HPLC is that the sample is punched directly into the tray that is used for analysis. Thus, although the possibility of an initial punching error remains the same, the risk of a pipetting error is eliminated.
The interpretation of results obtained with IEF requires much experience. Chromatograms obtained with HPLC are less subjective than IEF for common abnormalities because the results are observed in preset windows, although rarer variants are found outside these windows and can be harder to recognize. Caution is needed in interpreting Hbs D and E as detected by HPLC because many other variants are observed in these windows. For example, Hb D-Iran, D-Korle Bu, Abruzzo, and several ␥-chain variants elute in or near the window for Hb E, whereas Hb G-Philadelphia, G-Norfolk, Matsue-Oki, Winnipeg, Stanleyville II, and certain ␥-chain variants overlap in the window for Hb D. Hb Memphis was observed in the window for Hb S, but at a much lower concentration than would be expected in a true sickle cell trait. The overlap does not significantly affect the screening outcome, providing the laboratory has a suitable The "recalled" category shows those cases in which Hb H disease was queried by the laboratory. protocol for confirmatory testing and that the counseling strategy is planned with this in mind. Certain ␣-chain variants are only expressed neonatally in very low concentrations and can, therefore, be hard to detect. Hb Winnipeg was present in the sample we tested at only 0.7% in the window for Hb D despite being from a full-term baby, and it could be overlooked by inexperienced operators. We therefore suggest that any anomalous chromatogram be treated as a possible hemoglobin abnormality and repeated and/or recalled as appropriate.
Of the five abnormalities detected with IEF, but not with HPLC, three cases are still under investigation, and their clinical significance is not known. Two are ␤-chain variants that could be significant if present in the homozygous or double heterozygous state. The ␣-chain variant Hb Chicago has no known clinical significance. The new hemoglobin (Hb Harrow, ␤118 Phe-Cys) eluted in the window for Hb A on HPLC, giving the impression of a normal neonate. This baby had no Hb A, and we do not yet know the full clinical effects. At 1 year of age, however, the baby remains well and is maintaining his hemoglobin at 94 g/L. We do not think he will need a lifelong transfusion regime. This case does highlight the problems of identifying abnormal hemoglobins that fall in the window for Hb A.
The two heterozygotes initially missed by the IEF method (Hbs E and Abruzzo) were attributed to technical problems in focusing and staining the gels.
The performance of HPLC was comparable to IEF with few exceptions. The sensitivity, or proportion of positives correctly identified by HPLC, as calculated with the aid of a "truth table" (13 ) , is 0.9945 and reflects the five cases not detected with this method. True positives were based on the confirmed results detected with the reference method and, therefore, do not include those cases lost to followup. Because of the subjective detection of Hb Barts by IEF, these numbers have not been included in the truth table analysis. Because of the lack of clinical significance of ␥-chain variants and because their inclusion in the truth table analysis would give an erroneous impression of the real performance of HPLC, these numbers were also excluded. The positive predictive value is the proportion of patients with a positive result who are correctly identified, and is established at 0.9978. We have defined the two cases that were recalled for repeat testing for abnormalities on the basis of the HPLC analysis alone as false positives. The proportion of negatives correctly identified by HPLC, the specificity, was 0.9999, whereas the proportion of neonates with negative results who were correctly identified, the negative predictive value, was 0.9998. For a screening program such as this, it is most important that the specificity and negative predictive value are high. Any false positives will be eliminated by the use of new samples and the inclusion of different methods on follow-up.
HPLC detected fewer ␥-chain variants than IEF during the test period. Because these are generally clinically insignificant and disappear during the first few months of life, this could be considered an advantage because there would be fewer repeat samples requested and thus less anxiety and burden on the families involved.
Although dried blood spots are not the preferred medium for the detection of Hb Barts, we found that HPLC performed as well as IEF.
Hemoglobin carryover from one sample to the next was not observed during routine analysis using HPLC.
In summary, the HPLC method performed satisfactorily throughout the evaluation, and the results compared well with our existing IEF method for all common and clinically significant Hb abnormalities. The use of an automated system will produce substantial time saving in our laboratory.
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